Polymerase epsilon-based mouse and derived organoid models of intestinal cancer
基于聚合酶ε的小鼠和衍生的肠癌类器官模型
基本信息
- 批准号:10339162
- 负责人:
- 金额:$ 49.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-15 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY/ABSTRACT
Intestinal cancer is the 3rd most common malignancy and cause of cancer-related deaths in both men and
women. Unfortunately, recent advances in our understanding of the underlying intestinal biology and cancer-
related pathways have not translated to significantly improved patient outcomes. While numerous animal
models of intestinal cancer have been developed, mostly based on misregulation of the β-catenin pathway,
some key features of human cancers (particularly tumor mutational burden) now known to be critical for tumor
progression and therapy response, have not been adequately modelled or investigated in animal models of
intestinal cancer.
More recently, genome sequencing efforts led to the discovery of an intestinal cancer mutator phenotype
where single amino acid substitutions within proofreading domains of the housekeeping DNA polymerases
result in the highest mutation rates described in human cancers (ultramutation).
Unlike human cancers, genetically-engineered animal models exhibit very low mutation rates, limiting their
utility for studies of intratumoral heterogeneity and competition, immune responses, and immune checkpoint
therapies, now known to be essential aspects of human tumor biology. We propose to overcome these
limitations in intestinal cancer animal models by building upon 1) a strong track record in the generation of
cancer animal models and novel genetic tools for their development 2) a well-characterized conditional PoleP286R
allele that we previously used to develop a robust model of endometrial cancer and 3) expertise in genomics,
inflammation, intestinal cancer, and mouse models of intestinal disease. These models will be useful not only
to recapitulate POL-driven intestinal cancers, but also to humanize any intestinal cancer mouse model with
respect to mutational burden. This proposal is submitted in response to PAR-20-131 to expand and improve the
development of mammalian models for translational cancer research.
项目摘要/摘要
肠癌是男性和男性和癌症相关死亡的第三最常见的恶性肿瘤
女性。不幸的是,我们对潜在肠道生物学和癌症的理解的最新进展
相关途径尚未转化为显着改善患者预后。而无数动物
已经开发了肠癌的模型,主要是基于β-catenin途径的正调
人类癌症(尤其是肿瘤突变伯嫩)的一些关键特征现在对肿瘤至关重要
进展和治疗反应尚未在动物模型中进行充分建模或研究
肠癌。
最近,基因组测序工作导致发现了肠癌突变器表型
管家DNA聚合酶校对域中的单个氨基酸取代
导致人类癌症中描述的最高突变率(超露位)。
与人类的癌症不同,基因工程动物模型的突变率非常低,限制了它们
用于研究肿瘤内异质性和竞争,免疫回报和免疫访问的实用程序
疗法,现在已知是人类肿瘤生物学的重要方面。我们建议克服这些
通过建立肠道癌动物模型的局限
癌症动物模型和开发的新型遗传工具2)特征良好的条件性polep286r
我们以前用来开发可靠的子宫内膜癌模型的等位基因,3)基因组学专业知识,
炎症,肠癌和肠道疾病的小鼠模型。这些模型不仅有用
概括以pol驱动的肠癌,但也可以使任何肠道癌小鼠模型人性化
尊重突变负担。该建议是根据Par-20-131提交的,以扩展和改进
开发用于翻译癌症研究的哺乳动物模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
DIEGO H CASTRILLON的其他基金
Polymerase epsilon-based mouse and derived organoid models of intestinal cancer
基于聚合酶ε的小鼠和衍生的肠癌类器官模型
- 批准号:1070502510705025
- 财政年份:2022
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
Polymerase-mediated ultramutagenesis and carcinogenesis in mice
聚合酶介导的小鼠超突变和致癌作用
- 批准号:1054885310548853
- 财政年份:2019
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
Novel tumorigenic mechanisms of the LKB1 tumor suppressor
LKB1抑癌基因的新致瘤机制
- 批准号:98938289893828
- 财政年份:2016
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
Novel tumorigenic mechanisms of the LKB1 tumor suppressor
LKB1抑癌基因的新致瘤机制
- 批准号:91017589101758
- 财政年份:2016
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
Mouse Models and Translational Studies of Endometrial Cancer
子宫内膜癌的小鼠模型和转化研究
- 批准号:82104158210415
- 财政年份:2010
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
Mouse Models and Translational Studies of Endometrial Cancer
子宫内膜癌的小鼠模型和转化研究
- 批准号:86074598607459
- 财政年份:2010
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
Mouse Models and Translational Studies of Endometrial Cancer
子宫内膜癌的小鼠模型和转化研究
- 批准号:86063278606327
- 财政年份:2010
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
Mouse Models and Translational Studies of Endometrial Cancer
子宫内膜癌的小鼠模型和转化研究
- 批准号:82114028211402
- 财政年份:2010
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
Mouse Models and Translational Studies of Endometrial Cancer
子宫内膜癌的小鼠模型和转化研究
- 批准号:80245518024551
- 财政年份:2010
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
Mouse Models and Translational Studies of Endometrial Cancer
子宫内膜癌的小鼠模型和转化研究
- 批准号:78007397800739
- 财政年份:2010
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
相似国自然基金
吡喃糖骨架双功能催化剂设计及其应用于α-四取代碳-α-氨基酸衍生物的不对称催化合成
- 批准号:22361009
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
氟取代氨基酸修饰P450DA单加氧酶合成手性β-卤代醇的研究
- 批准号:32060215
- 批准年份:2020
- 资助金额:33 万元
- 项目类别:地区科学基金项目
氟代烷基取代的Cα-季碳氨基酸的不对称催化合成研究
- 批准号:21901074
- 批准年份:2019
- 资助金额:26.5 万元
- 项目类别:青年科学基金项目
功能化氮取代聚氨基酸的设计合成与性质研究
- 批准号:21704050
- 批准年份:2017
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
靶向肿瘤氨基酸转运体N-取代氨基酸PET显像剂的研制及其作用机理研究
- 批准号:81371584
- 批准年份:2013
- 资助金额:70.0 万元
- 项目类别:面上项目
相似海外基金
Polymerase epsilon-based mouse and derived organoid models of intestinal cancer
基于聚合酶ε的小鼠和衍生的肠癌类器官模型
- 批准号:1070502510705025
- 财政年份:2022
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
Polymerase-mediated ultramutagenesis and carcinogenesis in mice
聚合酶介导的小鼠超突变和致癌作用
- 批准号:1054885310548853
- 财政年份:2019
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
Mutagenesis, tumorigenesis and human DNA polymerase epsilon
诱变、肿瘤发生和人类 DNA 聚合酶 epsilon
- 批准号:92528049252804
- 财政年份:2016
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
The MTHFR C677T SNP exerts bipolar effects on colorectal cancer risk through the
MTHFR C677T SNP 通过以下方式对结直肠癌风险产生双极效应:
- 批准号:77134607713460
- 财政年份:2009
- 资助金额:$ 49.39万$ 49.39万
- 项目类别:
The MTHFR C677T SNP exerts bipolar effects on colorectal cancer risk through the
MTHFR C677T SNP 通过以下方式对结直肠癌风险产生双极效应:
- 批准号:79440337944033
- 财政年份:2009
- 资助金额:$ 49.39万$ 49.39万
- 项目类别: